280 related articles for article (PubMed ID: 9193363)
41. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.
McBride NC; Cavenagh JD; Ward MC; Grant I; Schey S; Gray A; Hughes A; Mills MJ; Cervi P; Newland AC; Kelsey SM
Leuk Lymphoma; 2001 Jun; 42(1-2):89-98. PubMed ID: 11699226
[TBL] [Abstract][Full Text] [Related]
42. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
[TBL] [Abstract][Full Text] [Related]
43. Clinical and pathological restaging in aggressive non-Hodgkin's lymphomas.
Mandelli F; Amadori S; Guglielmi C; Martelli M; Coluzzi S
Leukemia; 1991; 5 Suppl 1():38-41. PubMed ID: 1890864
[TBL] [Abstract][Full Text] [Related]
44. Gallium-67 scans as an adjunct to computed tomography scans for the assessment of a residual mediastinal mass in pediatric patients with Hodgkin's disease. A Pediatric Oncology Group study.
Weiner M; Leventhal B; Cantor A; Wimmer R; Berry DL; Cook B; Ducos R
Cancer; 1991 Dec; 68(11):2478-80. PubMed ID: 1933785
[TBL] [Abstract][Full Text] [Related]
45. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
[TBL] [Abstract][Full Text] [Related]
46. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
47. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
[TBL] [Abstract][Full Text] [Related]
48. Localized stage I-IE aggressive non-Hodgkin's lymphoma (NHL): results of prospective study with multimodality therapeutic approach.
De Sanctis V; Martelli M; Anticoli AP; Caronna R; Chirletti P; Giovannini M; Santarelli M; Enrici RM; Mandelli F
Anticancer Res; 2001; 21(6A):4169-72. PubMed ID: 11911313
[TBL] [Abstract][Full Text] [Related]
49. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial.
Ezzat AA; Ibrahim EM; Stuart RK; Ajarim D; Bazarbashi S; El-Foudeh MO; Rahal M; Al-Sayed A; Berry J
Med Oncol; 2000 Feb; 17(1):39-46. PubMed ID: 10713659
[TBL] [Abstract][Full Text] [Related]
50. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
51. Dose-intensified CHOP (double-CHOP) followed by consolidation with high-dose chemotherapy for high and high-intermediate risk aggressive non-Hodgkin's lymphomas.
Yamazaki T; Sawada U; Kura Y; Ito T; Kaneita Y; Yasukawa K; Horie T
Leuk Lymphoma; 2002 Nov; 43(11):2117-23. PubMed ID: 12533036
[TBL] [Abstract][Full Text] [Related]
52. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
53. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
54. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome.
Ha CS; Choe JG; Kong JS; Allen PK; Oh YK; Cox JD; Edmund E
Cancer; 2000 Sep; 89(6):1371-9. PubMed ID: 11002233
[TBL] [Abstract][Full Text] [Related]
55. A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL).
Child JA; Barnard DL; Cartwright SC; Lauder I; Simmons AV; Stone J; Thorogood J
Cancer Chemother Pharmacol; 1983; 11(3):153-8. PubMed ID: 6688970
[TBL] [Abstract][Full Text] [Related]
56. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
[TBL] [Abstract][Full Text] [Related]
57. The use of gallium-67 scintigraphy to monitor tumor response rates and predict long-term clinical outcome in patients with lymphoma.
Tuli MM; Al-Shemmari SH; Ameen RM; Al-Muhanadi S; Al-Huda FA; Ballani N; Khoshi M; Al-Enezi F; Bajciova V; Mottl H
Clin Lymphoma; 2004 Jun; 5(1):56-61. PubMed ID: 15245609
[TBL] [Abstract][Full Text] [Related]
58. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S;
Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633
[TBL] [Abstract][Full Text] [Related]
59. High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma.
Haioun C; Lepage E; Gisselbrecht C; Coiffier B; Doyen C; Morel P; Attal M; Tilly H; Deconinck E; Gaulard P; Reyes F
Ann Oncol; 1998; 9 Suppl 1():S5-8. PubMed ID: 9581235
[TBL] [Abstract][Full Text] [Related]
60. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?
Raderer M; Chott A; Drach J; Montalban C; Dragosics B; Jäger U; Püspök A; Osterreicher C; Zielinski CC
Ann Oncol; 2002 Jul; 13(7):1094-8. PubMed ID: 12176789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
